XERS
Xeris Biopharma Holdings, Inc.
Key Financials
Gross Profit
$19.7M
N/A
Operating Income
$24.9M
↑ 174.0%
Net Income
$554000
↑ 101.0%
Revenue
$291.8M
↑ 43.7%
Total Assets
$383.5M
↑ 18.7%
EPS (Diluted)
$0.00
↑ 100.0%
Total Liabilities
$369.8M
↑ 4.9%
Cash & Equivalents
$111.0M
↑ 55.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/2/2026 | View on SEC |
| 3 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 144 | 7/1/2026 | View on SEC |
| 144 | 7/1/2026 | View on SEC |
| 8-K | 6/30/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | XERS |
| Company Name | Xeris Biopharma Holdings, Inc. |
| CIK | 1867096 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 844-445-5704 |